Gut Microbiota and Gynecological Cancers: A Summary of Pathogenetic Mechanisms and Future Directions.

HPV cervical cancer dysbiosis endometrial cancer endometriosis estrobolome gynecological cancers immunotherapy metabolome microbiome microbiota oncobiome ovarian cancer

Journal

ACS infectious diseases
ISSN: 2373-8227
Titre abrégé: ACS Infect Dis
Pays: United States
ID NLM: 101654580

Informations de publication

Date de publication:
14 05 2021
Historique:
pubmed: 14 4 2021
medline: 24 6 2021
entrez: 13 4 2021
Statut: ppublish

Résumé

Over the past 20 years, important relationships between the microbiota and human health have emerged. A link between alterations of microbiota composition (dysbiosis) and cancer development has been recently demonstrated. In particular, the composition and the oncogenic role of intestinal bacterial flora has been extensively investigated in preclinical and clinical studies focusing on gastrointestinal tumors. Overall, the development of gastrointestinal tumors is favored by dysbiosis as it leads to depletion of antitumor substances (e.g., short-chain fatty acids) produced by healthy microbiota. Moreover, dysbiosis leads to alterations of the gut barrier, promotes a chronic inflammatory status through activation of toll-like receptors, and causes metabolic and hormonal dysregulations. However, the effects of these imbalances are not limited to the gastrointestinal tract and they can influence gynecological tumor carcinogenesis as well. The purpose of this Review is to provide a synthetic update about the mechanisms of interaction between gut microbiota and the female reproductive tract favoring the development of neoplasms. Furthermore, novel therapeutic approaches based on the modulation of microbiota and their role in gynecological oncology are discussed.

Identifiants

pubmed: 33848139
doi: 10.1021/acsinfecdis.0c00839
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

987-1009

Auteurs

Fulvio Borella (F)

Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Andrea Roberto Carosso (AR)

Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Stefano Cosma (S)

Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Mario Preti (M)

Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Giammarco Collemi (G)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Luca Bertero (L)

Pathology Unit, Department of Medical Sciences, University of Turin, 10126 Turin, Italy.

Chiara Benedetto (C)

Obstetrics and Gynecology Unit 1, Sant' Anna Hospital, Department of Surgical Sciences, University of Turin, 10126 Turin, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH